HealthDay News – For Health Workers (HCP), Vaccine Efficacy (VE) of approved mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna) against symptomatic COVID-19 illnesses are 82 and 94 percent for a single dose and for two doses, respectively a study published in the early release of the Weekly Report of the United States Centers for Morbidity and Mortality Control and Prevention, May 14th.
Tamara Pilishvili, Ph.D. from the CDC COVID-19 Response Team, and colleagues conducted a test-negative case-control study to evaluate mRNA COVID-19 VE against symptomatic disease in HCP at 33 US locations in 25 states.
The researchers found that after adjusting for age, race / ethnicity, and underlying illnesses, the VE of a single dose (measured 14 days after the first dose to six days after the second dose) was 82 percent in interim analyzes. The adjusted VE was 94 percent for two doses (measured at least seven days after the second dose).
Continue reading
“These interim results show that full vaccination with approved mRNA COVID-19 vaccines is highly effective in preventing symptomatic COVID-19 in HCP. This supports results from Phase III studies and additional evidence from recent observational studies,” write the authors. “In addition to following recommended infection control and prevention practices, an important component in fighting the US COVID-19 pandemic and protecting HCP is ensuring high coverage with safe and effective COVID-19 vaccines.”
Abstract / full text
Subjects:
COVID19 COVID19 Vaccine General Infectious Disease General Neurology
